Academic Clinical Trial Office, A-CTO, is a unit within the Hematology department which offers coordination of academic clinical trials for Nordic investigators in the Nordic Lymphoma group (NLG). The unit was officially initiated in December 2016 but has been emerging out of the experience obtained from coordinating large European trials at sponsor level over the last 10 years. A-CTO is able to fulfil and coordinate all aspects of clinical trials at sponsor level:

Click to see full size image

The unit is led by Francesco d’Amore, who is a professor of malignant lymphoproliferative diseases, and Helle Toldbod, who is the lead clinical trial manager. The A-CTO staff consists of an additional clinical trial manager and a secretary. From Q1 2018 the unit will expand with a data manager and a medical writer. Currently the unit coordinates 7 clinical trials, 5 initiated by NLG investigators and 2 run as European phase 3 trials. In Nordic and European trials, A-CTO coordinates the participation of 20 Nordic centers and a varying number of external partner sites.

Examples of studies are:

A phase 1/2 study of the combination of pixantrone, etoposide, bendamustine and, in Cd20 positive tumors, rituximab in patients with relapsed aggressive non-Hodgkin lymphomas of B- or T-cell phenotype - The P(R)EBEN study. EudraCT no. 2015-000758-39.

A phase II trial of ibrutinib, lenalidomide and rituximab for patients with relapsed/refractory mantle cell lymphoma. EudraCT no. 2013-005541-36.

A phase II trial of idelalisib in patients with relapsed/refractory diffuse large B-cell lymphoma. EudraCt no. 2016-001058-16.

Biomarker driven and dose intensified chemoimmunotherapy with early CNS prophylaxis in patients with less than 65 years with high risk diffuse large B-cell lymphoma. EudraCT no. 2015-002846-30.



For more information, please contact:

Francesco d’Amore
Tel. + 45 2326 6390

Helle Toldbod
Tel. + 45 7845 5855